Cellares Corporation’s CEO Fabian Gerlinghaus talks about the current limitations in cell therapy production and how, with $82 million in hand, its Cell Shuttle technology could resolve these.
Tech firm Cellares Corporation is looking to advance development of its cell therapy manufacturing platform, the Cell Shuttle.
Fabian Gerlingahaus, CEO of Cellares, spoke on the BioProcess Insider Expression Platform podcast
Having raised $82 million in its latest funding round, co-founder and CEO Fabian Gerlinghaus spoke about how the Cell Shuttles’ scalable, modular, and automated nature could be a gamechanger in the burgeoning space on the latest edition of the BioProcess Insider Expression Platform.
Listen to it below, or on iTunes, Google Podcasts, Spotify, or wherever you get your podcasts.
You May Also Like
schedl_b_and_w.jpg?width=100&auto=webp&quality=80&disable=upscale "Picture of Dan Stanton")
schedl_b_and_w.jpg?width=400&auto=webp&quality=80&disable=upscale "Dan Stanton")
